Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial

Table 2 Baseline and Post-Treatment/Placebo Laboratory Parameters

	Placebo Baseline	Placebo 6 months	Treatment Baseline	Treatment 6 months	p-value Baseline	p-value 6 months
Sodium (mEq/L)	140 ± 2	140 ± 3	138 ± 3	139 ± 2	0.11	0.24
Chloride	104 ± 4	104 ± 3	99 ± 21	104 ± 3	0.25	0.25
Co2	26.3 ± 2.9	25.8 ± 2.1	25.0 ± 3.0	25.5 ± 3.0	0.46	0.86
Potassium(mEq/L)	4.1 ± 0.8	4.1 ± 0.3	4.4 ± 0.3	4.3 ± 0.4	0.29	0.15
BUN (mg/dl)	22 ± 12	23 ± 13	24 ± 10	27 ± 13	0.46	0.33
Creatinine	1.3 ± 0.6	1.3 ± 0.6	1.2 ± 0.4	1.3 ± 0.5	0.29	0.86
Glucose (mg/dl)	115 ± 41	105 ± 36	118 ± 35	108 ± 23	0.64	0.79
Calcium (mg/dl)	8.9 ± 0.5	8.9 ± 0.8	9.0 ± 0.4	9.2 ± 0.4	0.71	0.18
Hemoglobin (g/dl)	14.1 ± 1.9	13.9 ± 1.5	14 ± 6.2	13.4 ± 1.5	0.63	0.51
Hematocrit (%)	44.5 ± 12.8	41.5 ± 4.4	42.6 ± 11.0	40 ± 4.6	0.39	0.31
BNP (pg/ml)	1800 ± 400	2300 ± 950	1600 ± 550	1400 ± 600	0.43	0.31
PTH (pg/ml)	90 ± 96*	93 ± 112	58 ± 28	45 ± 19	0.002	0.002
hsCRP (mg/ml)	3.5 ± 3.1	4.4 ± 3.9	5.4 ± 5.5	3.8 ± 1.1	0.42	0.18
25(OH)D (ng/ml)	20 ± 7	20 ± 9	19 ± 7	70 ± 28	0.8	0.001

Data are expressed as mean absolute values + standard deviation (SD). Abbreviations: Blood Urea Nitrogen (BUN), B-type Natriuretic Peptide (BNP), Parathyroid Hormone (PTH), high-sensitivity c-reactive protein (hsCRP), and 25-hydroxyvitamin D (25(OH)D)
*Indicates significant difference in PTH between placebo and treatment group at baseline, p=0.002

ISSN: 1471-2261